Inhibrx Inc

Inhibrx — Investor Presentation (May 2022)

44 slides from Inhibrx's investor presentation, May 16, 2022

  1. Slide 1: Outcomes Focused Innovation Driven May 2022

    Outcomes Focused Innovation Driven May 2022

  2. Slide 2: Forward-looking statements

    2 This presentation contains forward-looking statements. In some cases, you can identify forward-looking statements by the words “will,” “expect,” “intend,” “plan,” “objective,” “believe,” “estimate,” “potential,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminol

  3. Slide 3: Four differentiated clinical programs

    3 Four differentiated clinical programs INBRX-109 Tetravalent DR5 agonist + Single agent activity in chondrosarcoma + Potential rapid path to approval in chondrosarcoma, registration study initiated + Initial combination cohorts with data in 2H 2022: mesothelioma, pancreatic adenocarcinoma, colorect

  4. Slide 4: Why invest in Inhibrx?

    4 Why invest in Inhibrx? Backed by solid institutional investor base with substantial internal ownership Four differentiated clinical programs with potentially value- creating readouts in 2022/2023 KEY FINANCIAL HIGHLIGHTS* 39.0M $143.5M 44.7MRobust emerging pre-clinical pipeline Potential to reach

  5. Slide 5: Inhibrx at a glance

    5 Inhibrx at a glance + Experienced leadership team + Proven innovation and execution PARTNERSHIPS WITH INDUSTRY LEADERS All platforms and programs developed in-house with strong patent protection Inhibrx’s modular sdAb platform + Ability to precision engineer to specific target biology + Smaller th

  6. Slide 6: INBRX-101 Recombinant Alpha-1 Antitrypsin Fc-fusion Protein

    INBRX-101 Recombinant Alpha-1 Antitrypsin Fc-fusion Protein

  7. Slide 7: Functional AAT levels in healthy individuals vs. AATD patients

    7 Functional AAT levels in healthy individuals vs. AATD patients Disease history + Alpha-1 antitrypsin deficiency (AATD) is an inherited orphan respiratory disease characterized by deficient levels of alpha-1 antitrypsin (AAT) + This causes loss of lung function and decreased life expectancy + A sma

  8. Slide 8: Current standard of care

    8 Current standard of care + The current standard of care, plasma-derived AAT (pdAAT)**, dosed once weekly at 60 mg/kg, achieves an average level (Cavg) of functional AAT of 17.8 µM over the weekly dosing interval as calculated from steady-state area under the curve (AUC) values***. + Due to its sho

  9. Slide 9: Potential advantages of recombinant AAT Fc-fusion protein INBRX-101

    9 Potential advantages of recombinant AAT Fc-fusion protein INBRX-101 AAT Fc Potential to extend the dosing interval from weekly to monthly Has demonstrated potential to maintain patients in normal functional AAT range Recombinant manufacturing provides abundant supply with no pathogen risk

  10. Slide 10: INBRX-101 Topline results from Phase 1, Part 2

    10 Complete Ongoing INBRX-101 - Topline results from Phase 1, Part 2 N=18 * bronchoalveolar lavage N=6 40 mg/kg N=6 80 mg/kg* N=6 120 mg/kg* INBRX-101 Topline Results - 40, 80 or 120 mg/kg(Q3W) + MAD cohorts demonstrate Cavg of functional AAT of 40.4 µM over the 21-day dosing interval following the

  11. Slide 11: INBRX-101 Results from Phase 1, Part 1

    11 INBRX-101 - Results from Phase 1, Part 1 N=24 Complete N=6 10 mg/kg N=6 40 mg/kg N=6 120 mg/kg N=6 80 mg/kg Single ascending dose escalation (SAD) PART 1 + Favorable safety and tolerability profile with no drug-related SAEs at doses up to and including 120 mg/kg SAD + Dose related increases in ma

  12. Slide 12: INBRX-101 potential ~$3B annual U.S. revenue

    12 INBRX-101 has the potential to achieve ~$3B in annual U.S. revenue with expected rapid uptake in patients with severe AATD Notes: *Pricing assumption is for modelling purposes only Source: KOL Qualitative Interviews (n=~25); EvaluatePharma, Datamonitor, IQVIA, Fortune Business Insights, Analog an

  13. Slide 13: INBRX-101 potential to shift the treatment paradigm

    13 INBRX-101 has the potential to shift the treatment paradigm, expanding augmentation therapy to a broad group of AATD patients in the U.S. Notes: *Market Revenue for the “Less Severe” dependent on multitude of factors including pricing based on optimal dose in this population Sources: KOL Intervie

  14. Slide 14: INBRX-109 Tetravalent DR5 Agonist

    INBRX-109 Tetravalent DR5 Agonist

  15. Slide 15: Tetravalent DR5 agonist

    15 Tetravalent DR5 agonist + Death receptor 5 (DR5) is a receptor for the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) + DR5 activation naturally eliminates damaged and neoplastic cells DR5: sdAb DR5: sdAbDR5: sdAb DR5: sdAb 105 kDa Fc: effector function disabled

  16. Slide 16: INBRX-109 is a best-in-class DR5 agonist

    16 INBRX-109 is a best-in-class DR5 agonist CANDIDATE VALENCY SIZE (KDA) INBRX-109 Tetravalent 105 TAS-2661 Tetravalent 60 Eftozanermin alpha (TRAIL-Fc fusion) Hexavalent 167 GEN10291,2 Dodecavalent 150 ka (2x mAbs) IGM-8444 Decavalent3 ~950 Dulanermin (recombinant TRAIL) Trivalent 150 Tigatuzumab B

  17. Slide 17: Preliminary Phase 1 data in chondrosarcoma

    17 Best Response 3mo 6mo 9mo 12mo SD (-20%) 77wks SD (-11%) 64wks SD (-7%) 62wks PR (-61%) SD (-13%) SD (+3%) PR (-32%) SD (-4%) ** SD (-1%) ► SD (-3%) SD (-20%) ► SD (+5%) SD (+3%) * SD (-5%) * SD (+5%) SD (+7%) PD (+31%) PD (+16%) Pending ► Pending ► Weeks 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

  18. Slide 18: INBRX-109 Phase 2 registration-enabling study design in chondrosarcoma

    18 ENDPOINTS Primary: Progression free survival Secondary: Overall survival, quality of life, overall response rate, duration of response, disease control rate, safety, etc. INBRX-109 Phase 2 potentially registration-enabling study design in chondrosarcoma Randomization Conventional chondrosarcoma,

  19. Slide 19: Chondrosarcoma patient flow and prevalent patient pool

    19 Many patients with local disease eventually progress to unresectable or metastatic chondrosarcoma, providing an annual prevalent patient pool of ~2.5K in the U.S. At Diagnosis Recurrence at 10 years Conventional chondorsarcoma Local (~75%) Low grade resectable (~55%) Metastatic (~25%) High grade

  20. Slide 20: INBRX-109 potential ~$1B annual revenue

    20 Based on current trends and lack of approved options, INBRX-109 has the potential to achieve ~$1B in annual revenue with rapid uptake post launch Notes: *Pricing assumption is for modelling purposes only based on analogous market research for oncology products in rare indications; Sources: KOL qu

  21. Slide 21: Phase 1 single agent data in mesothelioma

    21 Best response 3mo 6mo 9mo SD (-24%) * SD (-17%) SD (-12%) PR (-100%) SD (-22%) SD (-20%) SD (-12%) SD (-5%) SD (-2%) SD (+9%) SD (+13%) SD (+16%) SD (+1%) * PD PD PD PD (+25%) PD (+33%) PD (+33%) Weeks 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35

  22. Slide 22: INBRX-109 on the horizon

    22 Ongoing Ongoing POTENTIAL FUTURE OPPORTUNITIES Solid tumors + IAP antagonists Hematologic tumors + Bcl-2 inhibitors NSCLC + various combo agents Gastric and colon cancer + various combo agents Additional sarcoma indications INBRX-109 on the horizon Combination studies Pancreatic adenocarcinoma 2n

  23. Slide 23: INBRX-106 Hexavalent OX40 Agonist

    INBRX-106 Hexavalent OX40 Agonist

  24. Slide 24: Hexavalent OX40 agonist

    24 Hexavalent OX40 agonist OX40 is a co-stimulatory receptor on activated T-cells designed to: + Provide co-stimulation to activated T-cells + Reverse regulatory T-cell induced immune suppression + Enhance T-cell functionality + Provide additional benefit in combination with PD-1 blockade OX40: sdAb

  25. Slide 25: INBRX-106 is a best-in-class OX40 agonist

    25 INBRX-106 is a best-in-class OX40 agonist CANDIDATES VALENCY ISOTYPE LIGAND BLOCKING STATUS INBRX-106 Hexa- IgG1 N Ph 1 (2019) MOXR-0916 Bi- IgG1 Y Discontinued GSK-3174998 Discontinued BMS-986178 Ph 1 (2016) INCAGN-1949 Ph 1 (2016) ABBV-368 Ph 1 (HNSCC, 2020) IBI-101 Ph 1 (2018) MEDI-0562 Discon

  26. Slide 26: INBRX-106 Phase 1 in combination with Keytruda

    26 Complete PART 3 + Examples of activity: o Two durable PRs > 6 months and treatment ongoing (nasopharyngeal carcinoma and uveal melanoma, both CPI-naïve) o One double-digit reduction in tumor size with duration >4 months (CPI-exposed cutaneous melanoma) + Well-tolerated with mild or moderate immun

  27. Slide 27: INBRX-106 Phase 1 preliminary single agent activity

    27 Complete INBRX-106 Phase 1 preliminary single agent activity Ongoing Dose escalation Dose expansion PART 1 + 4/10 response evaluable NSCLC & melanoma patients with duration of stable disease* greater than 6 months (three CPI-exposed patients and one CPI-naïve uveal melanoma patient) + Longest dur

  28. Slide 28: Market opportunity for INBRX-106 and INBRX-105

    28 Market opportunity for INBRX-106 and INBRX-105 The figures on this slide represent market research estimates from Evaluate Pharma *Keytruda™ and Opdivo® go off patent in 2028 $14.4 $7.9 $2.9 $2.0 $1.0 $28.2$27.1 $14.2 $7.4 $4.7 $10.1 $63.5 $0 $10 $20 $30 $40 $50 $60 $70 KEYTRUDA* OPDIVO* TECENTRI

  29. Slide 29: INBRX-105 PD-L1 x 4-1BB Multispecific

    INBRX-105 PD-L1 x 4-1BB Multispecific

  30. Slide 30: PD-L1 x 4-1BB multispecific

    30 PD-L1 x 4-1BB multispecific + Designed to provide spatially-restricted 4-1BB agonism at sites of PD-L1 expression + Highly expressed on tumor infiltrating immune cells, 4-1BB signaling promotes prolonged T-cell survival memory formation + Constitutive 4-1BB agonism has achieved anti-tumor respons

  31. Slide 31: INBRX-105 is a potential best-in-class 4-1BB agonist

    31 INBRX-105 is a potential best-in-class 4-1BB agonist CANDIDATE FORMAT 4-1BBL BLOCKING INBRX-105 Bivalent/Bivalent No Gen-1064 Monovalent/Monovalent n/a MCLA-145 Monovalent/Monovalent Yes FS222 Bivalent/Bivalent n/a PRS-343 Bivalent/Bivalent No ND021 Monovalent/Monovalent n/a CANDIDATE IGG SUBCLAS

  32. Slide 32: INBRX-105 Phase 1 trial design

    32 PlannedOngoingOngoingComplete INBRX-105 Phase 1 trial design Single agent: PD-L1+ basket Single agent dose escalation Single agent dose expansion N=80N=32 N=15+N=32 No pre-screening, all-comers + 8/18 (44%) at dose levels ≥ 0.1 mg/kg achieved stable disease + Patients were not pre-screened for PD

  33. Slide 33: Molecular Targeted Cytokine (MTC) Platform

    Molecular Targeted Cytokine (MTC) Platform A Targeted Detuned IL-2 Platform

  34. Slide 34: Affinity differential enables directed IL-2 expansion

    34 Affinity differential enables directed IL-2 expansion/enhancement of specific cell types High affinity antibody targeting INHIBRX has developed sdAbs to an extensive number of antigens + T-cell or NK cell subsets + Activating/co-stimulatory receptors + Inhibitory receptors + Exhaustion markers Pr

  35. Slide 35: INBRX-121 NKp46 Targeted Detuned IL-2

    INBRX-121 NKp46 Targeted Detuned IL-2

  36. Slide 36: INBRX-121 expanded the NK cell population and enhanced cytotoxicity

    36 INBRX-121 expanded the NK cell population and enhanced cytotoxicity + NKp46 is an NK-specific marker that maintains expression on tumor-infiltrating NK cells + Proprietary IL2-X engineering ensures specific modulation of NK Cells without impacting T-cell subsets (Tcon and Treg) NKp46 sdAb NKp46 s

  37. Slide 37: INBRX-121 poised to bring NK cells to the forefront of immunotherapy

    37 INBRX-121 INBRX-121 is poised to bring NK cells to the forefront of immunotherapy NK NK NK NK NK NK NK NK NK NK Improved NK Activity Safety with durability Single agent Activated NK cells exhibit immediate cytotoxicity Multiple potential paths forward Combination therapy Enhances the activity of

  38. Slide 38: Expanded mouse NK cells and enhanced cytotoxic potential

    38 Expanded mouse NK cells and enhanced their cytotoxic potential 0 2,000 3,000 4,000 5,000 KL RG 1 le ve ls 5,000 10,000 15,000 20,000 Gr an zy m e B le ve ls M ax . f ol d- ch an ge (r el at iv e to v eh ic le ) 0 5 10 20 25 15 NK cells CD8 T cells Tregs CD4+Tcon B cells NK cell cytolytic activity

  39. Slide 39: Synergized with approved therapeutic antibodies

    39 Synergized with approved therapeutic antibodies INBRX-121 synergized with Rituxan® in a subcutaneous Raji tumor model resulting in complete tumor regression Dosing Days TREATMENT COMPLETE RESPONSES Rituxan® 0/10 INBRX-121 + Rituxan® 9/10 Raji tumor growth 0 42 Time (days) 0 Tu m or Vo lu m e (m m

  40. Slide 40: INBRX-121 safely expanded NK cells in non-human primates

    40 INBRX-121 safely expanded NK cells in non-human primates 8% 82% 10% 41.5% 51.5% 7% Expanded NK cells in a dose-dependent manner (up to 12-fold) that persists for more than 21 days and can be dosed multiple times safely Tolerated at all tested doses (up to 30 mg/kg) with no clinical signs of toxic

  41. Slide 41: Expanded NK cells from Lymphoma patients

    41 Expanded NK cells from Lymphoma patients NK cells from Lymphoma patients expressed NKp46 at levels similar or above that of healthy donors Patient NK cells responded to stimulation with INBRX-121 by upregulating pSTAT5 and showed an increased proliferative potential - + Healthy Donor 0 20 40 % p

  42. Slide 42: Expanded NK cells while enhancing cytotoxic capacities

    42 Expanded the number of NK cells while enhancing their individual cytotoxic capacities INBRX-121 increased NK cell-mediated killing of Raji cells in the presence of a Rituximab sequence analog (Anti-hCD20- hIgG1). Raji cell killing after INBRX-121 pre-incubation Effector: target ratio 0 % Ta rge t

  43. Slide 43: Near term expected clinical milestones

    43 Near term expected clinical milestones 1H 2022 2H 2022 (OX40) / Keytruda initial dose expansion cohort data (AAT) Additional Phase 1 data (PD-L1 x 41BB) Keytruda dose escalation data (PD-L1 x 41BB) Keytruda dose expansion cohort data (DR5) Initial mesothelioma, Ewing sarcoma, pancreatic cancer, a

  44. Slide 44: Contact: La Jolla, CA, www.inhibrx.com

    11025 N. Torrey Pines Rd Ste 200 La Jolla, CA 92037 www.inhibrx.com

Inhibrx — Investor Presentation (May 2022) on 6ix